FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression

Oncogene

Volumn 35, Issue 33, 2016, Pages 4335-4344

  Zhao, J C ^a   Fong, K W ^a   Jin, H J ^a   Yang, Y A ^a   Kim, J ^a   Yu, J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; TRANSCRIPTION FACTOR GATA 2; AR PROTEIN, HUMAN; FOXA1 PROTEIN, HUMAN; GATA2 PROTEIN, HUMAN;

ARTICLE; CELL REPROGRAMMING TECHNIQUE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HORMONAL REGULATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN BINDING; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; GENETIC TRANSCRIPTION; GENETICS; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; GATA2 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSCRIPTION, GENETIC;

EID: 84954516734     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.496     Document Type: Article

References (29)

1. Gao N, Zhang J, Rao MA, Case TC, Mirosevich J, Wang Y et al. The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol 2003; 17: 1484-1507.
2. Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 2008; 132: 958-970.
3. Jozwik KM, Carroll JS. Pioneer factors in hormone-dependent cancers. Nat Rev Cancer 2012; 12: 381-385.
4. Sekiya T, Muthurajan UM, Luger K, Tulin AV, Zaret KS. Nucleosome-binding affinity as a primary determinant of the nuclear mobility of the pioneer transcription factor FoxA. Genes Dev 2009; 23: 804-809.
5. Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 2011; 474: 390-394.
6. Jin HJ, Zhao JC, Wu L, Kim J, Yu J. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program. Nat Commun 2014; 5: 3972.
7. Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J 2011; 30: 3962-3976.
8. Jin HJ, Zhao JC, Ogden I, Bergan RC, Yu J. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Cancer Res 2013; 73: 3725-3736.
9. Gerhardt J, Montani M, Wild P, Beer M, Huber F, Hermanns T et al. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. Am J Pathol 2012; 180: 848-861.
10. Zhang C, Wang L, Wu D, Chen H, Chen Z, Thomas-Ahner JM et al. Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer Res 2011; 71: 6738-6748.
11. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007; 27: 380-392.
12. Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med 2013; 19: 1023-1029.
13. Pevny L, Simon MC, Robertson E, Klein WH, Tsai SF, D'Agati V et al. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature 1991; 349: 257-260.
14. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J 1997; 16: 3965-3973.
15. Yu M, Riva L, Xie H, Schindler Y, Moran TB, Cheng Y et al. Insights into GATA-1-mediated gene activation versus repression via genome-wide chromatin occupancy analysis. Mol Cell 2009; 36: 682-695.
16. Boyes J, Omichinski J, Clark D, Pikaart M, Felsenfeld G. Perturbation of nucleosome structure by the erythroid transcription factor GATA-1. J Mol Biol 1998; 279: 529-544.
17. Bossard P, Zaret KS. GATA transcription factors as potentiators of gut endoderm differentiation. Development 1998; 125: 4909-4917.
18. He B, Lanz RB, Fiskus W, Geng C, Yi P, Hartig SM et al. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. Proc Natl Acad Sci USA 2014; 111: 18261-18266.
19. Wu D, Sunkel B, Chen Z, Liu X, Ye Z, Li Q et al. Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer. Nucleic Acids Res 2014; 42: 3607-3622.
20. Vidal SJ, Rodriguez-Bravo V, Quinn SA, Rodriguez-Barrueco R, Lujambio A, Williams E et al. A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer Cell 2015; 27: 223-239.
21. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 2011; 20: 457-471.
22. Zhao JC, Yu J, Runkle C, Wu L, Hu M, Wu D et al. Cooperation between Polycomb and androgen receptor during oncogenic transformation. Genome Res 2012; 22: 322-331.
23. Wu Q, Dhir R, Wells A. Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Mol Cancer 2012; 11: 3.
24. Godoy P, Cadenas C, Hellwig B, Marchan R, Stewart J, Reif R et al. Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response. Breast Cancer 2014; 21: 491-499.
25. Andreu-Vieyra C, Lai J, Berman BP, Frenkel B, Jia L, Jones PA et al. Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells. Mol Cell Biol 2011; 31: 4648-4662.
26. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-243.
27. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012; 44: 685-689.
28. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010; 17: 443-454.
29. Wu L, Runkle C, Jin HJ, Yu J, Li J, Yang X et al. CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor. Oncogene 2013; 33: 504-513.